Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Non-Hodgkins Lymphoma

High-dose cyclophosphamide, BCNU, and VP-16 (CBV) conditioning before allogeneic stem cell transplantation for patients with non-Hodgkin's lymphoma

Bone Marrow Transplantation volume 31, pages 441–446 (2003)Cite this article

Summary:

Allogeneic stem cell transplantation (SCT) has been shown to be a curative therapy for some patients with non-Hodgkin's lymphoma (NHL). Total-body irradiation and high-dose cyclophosphamide combinations are the most established conditioning regimens used in this setting. We examined the efficacy and toxicity of cyclophosphamide, BCNU, and VP-16 (CBV) as a suitable chemotherapy-only regimen for NHL patients. In total, 18 patients, median age 42 years, with NHL were treated with CBV followed by allotransplant. Patients had received a median of two prior chemotherapy regimens. Median times to neutrophil and platelet recovery were 19 and 15 days, respectively. Interstitial pneumonitis occurred in one patient. There have been four relapses after a median follow-up of 39 months. Overall, there were four deaths, one because of relapse. The 2-year estimates of relapse-free and overall survival are 56 and 76%, respectively. CBV is a safe and an effective alternative to TBI-containing regimens before allogeneic SCT for NHL.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Chopra R, Goldstone AH, Pearce R et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case controlled analysis of the European Bone Marrow Transplant Group Registry data. J Clin Oncol 1992; 10: 1690–1695.

    Article  CAS  PubMed  Google Scholar 

  2. Milpied N, Fielding AK, Pearce RM . Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol 1996; 14: 1291–1296.

    Article  CAS  PubMed  Google Scholar 

  3. Ratanatharathorn V, Uberti J, Karanes C et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 1994; 84: 1050–1055.

    CAS  PubMed  Google Scholar 

  4. Copelan EA, Kapoor N, Gibbins B et al. Allogeneic marrow transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplant 1990; 5: 47–50.

    CAS  PubMed  Google Scholar 

  5. Applebaum FR, Sullivan KM, Buckner CD et al. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. J Clin Oncol 1987; 5: 1340–1347.

    Article  Google Scholar 

  6. Petersen, FB, Appelbaum FR, Hill R et al. Autologous marrow transplantation for malignant lymphoma. A report of 101 cases from Seattle. J Clin Oncol 1990; 8: 638–647.

    Article  CAS  PubMed  Google Scholar 

  7. Van Besien K, Sobocinski KA, Rowlings PA et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 1998; 92: 1832–1838.

    CAS  PubMed  Google Scholar 

  8. Clift RA, Buckner CD, Appelbaum FR et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood 1991; 8: 1660–1667.

    Google Scholar 

  9. Wheeler C, Khurshid A, Ibrahim J et al. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV). Leuk Lymphoma 2001; 40: 499–509.

    Article  CAS  PubMed  Google Scholar 

  10. Kolb HJ, Bender Götze Ch . Late complications after allogeneic bone marrow transplantation for leukemia. Bone Marrow Transplant 1990; 6: 61–67.

    CAS  PubMed  Google Scholar 

  11. Gribben JG, Linch JG, and Singer CRJ . Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood 1989; 73: 340–344.

    CAS  PubMed  Google Scholar 

  12. Wheeler C, Antin JH, Churchill WH et al. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. J Clin Oncol 1990; 8: 648–656.

    Article  CAS  PubMed  Google Scholar 

  13. Gulati SC, Shank B, Black P et al. Autologous bone marrow transplantation for patients with poor-prognosis lymphoma. J Clin Oncol 1988; 6: 1303–1313.

    Article  CAS  PubMed  Google Scholar 

  14. Demirer T, Weaver CH, Buckner CD et al. High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy. J Clin Oncol 1995; 13: 596–602.

    Article  CAS  PubMed  Google Scholar 

  15. Philips GL, Reece DE, Barnett MJ et al. Allogeneic marrow transplantation for refractory Hodgkins disease. J Clin Oncol 1989; 7: 1039–1045.

    Article  Google Scholar 

  16. Zander AR, Culbert S, Jagannath S et al. High dose cyclophosphamide, BCNU, and VP-16 (CBV) as a conditioning regimen for allogeneic bone marrow transplantation for patients with acute leukemia. Cancer 1987; 59: 1083–1086.

    Article  CAS  PubMed  Google Scholar 

  17. Cheson BD, Horning SJ, Coiffier B et al. Report of an International Workshop to standardize response criteria for non-Hodgkin's Lymphomas. J Clin Oncol 1999; 17: 1244–1253.

    Article  CAS  PubMed  Google Scholar 

  18. Phillips GL, Reece DE . HLA-identical sibling hematopoietic stem cell transplantation for the non-Hodgkin's lymphomas and Hodgkin's disease. In: Atkinson K (ed.). Clinical Bone Marrow and Blood Stem Cell Transplantation. Cambridge University Press: Cambridge, 2000, pp 500–514.

    Google Scholar 

  19. Michallet M, Archimbaud E, Bandini G et al. HLA-identical sibling bone marrow transplantation in younger patient with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry. Ann Int Med 1996; 124: 311–315.

    Article  CAS  PubMed  Google Scholar 

  20. Pavletic ZS, Arrowsmith ER, Bierman PJ et al. Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. Bone Marrow Transplant 2000; 25: 717–722.

    Article  CAS  PubMed  Google Scholar 

  21. Coiffier B . Which treatment for mantle-cell lymphoma patients in 1998. J Clin Oncol 1998; 16: 3–7.

    Article  CAS  PubMed  Google Scholar 

  22. Haas R, Brittinger G, Meusers P et al. Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma. Leukemia 1996; 10: 1975–1983.

    CAS  PubMed  Google Scholar 

  23. Hiddemann W, Dreyling M, Pfreundschuh M et al. Myeloablative radiochemotherapy followed by autologous blood stem cell transplantation leads to a significant prolongation of event-free survival in patients with mantle cell lymphoma (MCL) – results of a prospective randomized European intergroup study. Blood 2001; 98: 861a (absract 3572).

    Google Scholar 

  24. Khouri IF, Saliba RM, Younes A et al. Allogeneic transplantation for poor risk mantle cell lymphoma (MCL): chemosensitivity predicts superior outcome. Blood 2001; 98: 416a (abstract 1745).

    Article  Google Scholar 

  25. Gianni AM, Bregni M, Siena S et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336: 1290–1297.

    Article  CAS  PubMed  Google Scholar 

  26. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545.

    Article  CAS  PubMed  Google Scholar 

  27. Blume K, Buckner D . Workshop: high dose etoposide containing regimens. Bone Marrow Transplant 1995;15: S207–S212.

    Google Scholar 

  28. Wheeler C, Strawderman M, Ayash L et al. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide. J Clin Oncol 1993; 11: 1085–1091.

    Article  CAS  PubMed  Google Scholar 

  29. Bierman PJ, Vose JM, Anderson JR et al. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 445–452.

    Article  CAS  PubMed  Google Scholar 

  30. Stone RM . Myelodysplastic syndrome after autologous bone marrow transplantation for lymphoma: The price of progress? Blood 1994; 83: 3437.

    CAS  PubMed  Google Scholar 

  31. Jones RJ, Ambinder RF, Piantadosi S et al. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991; 77: 649–653.

    CAS  PubMed  Google Scholar 

  32. Mittenbauer M, Neumeister P, Kalhs P et al. Long-term clinical and molecular remission after allogeneic stem cell transplantation (SCT) in patients with poor prognosis non-Hodgkin's lymphoma. Leukemia 2001; 15: 635–641.

    Article  Google Scholar 

  33. Stein RS, Greer JP, Goodman S et al. Intensified preparative regimens and allogeneic transplantation in refractory or relapsed intermediate and high grade non-Hodgkin's lymphoma. Leuk Lymphoma 2001; 41: 343–352.

    Article  CAS  PubMed  Google Scholar 

  34. Devergie A, Blaise D, Attal M et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan–cytoxan versus cytoxan–total body irradiation as preparative regime: a report from the French society of bone marrow graft (SFGM). Blood 1995; 85: 2263–2268.

    CAS  PubMed  Google Scholar 

  35. Ringden O, Lapopin M, Tura S et al. A comparison of busulphan versus total body irradiation combined with cyclosphosphaide as conitioning for autograft or allograft bone marrow transplantation in patients with acute leukemia. Br J Haematol 1996; 93: 637–645.

    Article  CAS  PubMed  Google Scholar 

  36. Horning S, Chao N, Negrin R et al. The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data. Ann Oncol 1991; 2: 47–50.

    Article  PubMed  Google Scholar 

  37. Williams CD, Goldstone AH, Pearce RM et al. Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry. J Clin Oncol 1996; 14: 2454.

    Article  CAS  PubMed  Google Scholar 

  38. Van der Jagt RHC, Appelbaum FR, Petersen FR et al. Busulfan and cyclophosphamide as a preparative regimen for bone marrow transplantation in patients with prior chest radiotherapy. Bone Marrow Transplant 1991; 8: 211–215.

    CAS  PubMed  Google Scholar 

  39. Reece DE, Barnett MJ, Connors JM et al. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1991;9: 1871–1879.

    Article  CAS  PubMed  Google Scholar 

  40. Jagannath S, Dicke DA, Armitage JO et al. High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease. Ann Intern Med 1986; 104: 163–168.

    Article  CAS  PubMed  Google Scholar 

  41. Chao N, Kastrissios H, Long G et al. A new preparatory regimen for autologous bone marrow transplantation for patients with lymphoma. Cancer 1995; 75: 1354–1359.

    Article  CAS  PubMed  Google Scholar 

  42. Haioun C, Lepage E, Gisseelbrecht C et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol – a Groupe d’Etude des Lymphomas de l’Adulte study. J Clin Oncol 2000; 18: 3025–3030.

    Article  CAS  PubMed  Google Scholar 

  43. Maris M, Niederwieser D, Sandmaier B . Nonmyeloablative hematopoeitic stem cell transplants (HSCT) using 10/10 HLA antigen matched unrelated donors (URDs) for patients with advanced hematologic malignancies ineligible for conventional HSCT. Blood 2001; 98 (abstract 3563).

  44. Mitterbauer M, Neumeister P, Kalhs P et al. Long-term clinical and molecular remission after allogeneic stem cell transplantation (SCT) in patients with poor prognosis non-Hodgkin's lymphoma. Leukemia 2001; 15: 635–641.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. W Levy

    Present address: Fred Hutchinson Cancer Research Center, Seattle, USA

  2. Q Liu: Cancer Center, Umass Medical School, Worcester MA, USA.

  3. K Ballen: Massachusetts General Hospital, Boston, MA, USA.

Authors and Affiliations

  1. Division of Hematology and Oncology, Umass Memorial Healthcare, North Worcester, MA, USA

    H A Rossi, P S Becker, R V B Emmons, P Westervelt, W Levy, Q Liu, Y Clark & K Ballen

Authors
  1. H A Rossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P S Becker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R V B Emmons
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P Westervelt
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. W Levy
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Q Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Y Clark
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. K Ballen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rossi, H., Becker, P., Emmons, R. et al. High-dose cyclophosphamide, BCNU, and VP-16 (CBV) conditioning before allogeneic stem cell transplantation for patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 31, 441–446 (2003). https://doi.org/10.1038/sj.bmt.1703874

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703874

Keywords

Search

Advanced search

Quick links